Page last updated: 2024-11-06

1-palmitoylphosphatidylethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-palmitoylphosphatidylethanolamine (16:0-PE) is a type of phospholipid, a key component of cell membranes. It plays a crucial role in maintaining membrane structure and fluidity. Its synthesis involves the attachment of palmitic acid (a saturated fatty acid) to the sn-1 position of phosphatidylethanolamine (PE). 16:0-PE is involved in various cellular processes, including signal transduction, membrane trafficking, and cell growth. It is also a precursor to other important phospholipids, such as phosphatidylcholine (PC). Research on 16:0-PE focuses on its role in membrane organization, its involvement in diseases such as Alzheimer's and Parkinson's, and its potential use as a therapeutic target.'

Cross-References

ID SourceID
PubMed CID89229
CHEBI ID176760
SCHEMBL ID10493775
MeSH IDM0185149

Synonyms (22)

Synonym
CHEBI:176760
13190-01-7
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] hexadecanoate
P-1135
P-1110
P-1140
1-palmitoylcephalin
1-palmitoyl-rac-glycero-3-phosphoethanolamine
1-palmitoylphosphatidylethanolamine
(1)-3-(((2-aminoethoxy)hydroxyphosphinoyl)oxy)-2-hydroxypropyl hexadecanoate
einecs 243-330-2
19805-23-3
1-palmitoyl-sn-glycerophosphoethanolamine
n-palmitoylphosphatidylethanolamine
3-palmitoyl-dl-glycero-1-phosphorylethanolamine
1-ppem
hexadecanoic acid, 3-(((2-aminoethoxy)hydroxyphosphinyl)oxy)-2-hydroxypropyl ester
SCHEMBL10493775
DTXSID20927386
3-{[(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-2-hydroxypropyl hexadecanoate
16:0 lpe
PD088584
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-acyl-sn-glycero-3-phosphoethanolamineA 1-O-acylglycerophosphoethanolamine having (R)-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's3 (42.86)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]